NIH R01 · 2025
Immunometabolic Biomarkers to Advance TB Diagnosis and Treatment Monitoring
PROJECT SUMMARY/ABSTRACT Among the 10.6 million persons estimated to develop tuberculosis (TB) disease each year, ~40% are never notified to public health programs, leading to delays in treatment and increased TB transmission and mortality. Current diagnostics for pulmonary TB require microbiologic testing of sputum specimens, which is often unavailable in primary care settings in low- and middle-income countries, where most TB disease occurs. Further, clinicians lack reliable measures of TB disease severity and treatment response, limiting their ability to individualize treatment regimens and duration. There is a tremendous need for rapid, point-of-care, biomarker- based tests that can be…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.